Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iafrate

Showing results (491-500 of 580) with videos related to

Pageof 58
Sort By:
Journal of Neuropathology and Experimental Neurology|December 4, 2020
Somatic Focal Copy Number Gains of Noncoding Regions of Receptor Tyrosine Kinase Genes in Treatment-Resistant EpilepsyVarshini Vasudevaraja, Javier Hernaez Rodriguez, Cristiana Pelorosso, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Cancer|November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
The Oncologist|August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric CancersSurendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
The Journal of Infectious Diseases|September 9, 2020
High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, MassachusettsVivek Naranbhai, Christina C Chang, Wilfredo F Garcia Beltran, et al.
Cancer|February 9, 2022
Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancerConnor J O'Boyle, Giulia Siravegna, Shohreh Varmeh, et al.
Pageof 58

Showing results (491-500 of 580) with videos related to

Sort By:
Pageof 58
Journal of Neuropathology and Experimental Neurology|December 4, 2020
Somatic Focal Copy Number Gains of Noncoding Regions of Receptor Tyrosine Kinase Genes in Treatment-Resistant EpilepsyVarshini Vasudevaraja, Javier Hernaez Rodriguez, Cristiana Pelorosso, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
The New England Journal of Medicine|September 30, 2014
Crizotinib in ROS1-rearranged non-small-cell lung cancerAlice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Cancer Discovery|May 3, 2015
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR InhibitorZofia Piotrowska, Matthew J Niederst, Chris A Karlovich, et al.
Cancer|November 14, 2018
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemiaAndrew M Brunner, Donna S Neuberg, Seth A Wander, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2012
ROS1 rearrangements define a unique molecular class of lung cancersKristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, et al.
The Oncologist|August 22, 2020
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric CancersSurendra Pal Chaudhary, Eunice L Kwak, Katie L Hwang, et al.
The Journal of Infectious Diseases|September 9, 2020
High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, MassachusettsVivek Naranbhai, Christina C Chang, Wilfredo F Garcia Beltran, et al.
Cancer|February 9, 2022
Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancerConnor J O'Boyle, Giulia Siravegna, Shohreh Varmeh, et al.
Pageof 58